Research and Development Overview
In June 2004 Aus Bio’s laboratories moved to Monash University’s Department of Pharmacology where close links have been forged with key Department personnel and joint funding opportunities are being pursued.
Aus Bio’s diverse R & D pipeline reduces the known risks associated with scientific and commercialisation of successful drug discovery. The Company’s policy to mitigate these risks allows management of the current projects according to each project’s stage of development from Discovery Chemistry through to Lead Optimisation, Selection and Early Stage of Clinical or Commercial Development.
During the year management pursued and fostered key value adding strategic, scientific and commercial partnerships. The Company and employees have at all times maintained the highest ethical, scientific and corporate principles.
Current Research Projects
Project MD 920 The Development of Novel Wound Healing Compounds for Chronic Wounds and Lower Limb Venous Ulceration.
Project MD 960 The Development of Novel Treatments for the Management of Diabetes Mellitus and Insulin Resistance.
Project PC 2000 The Development of Novel Immune Modulators for the Treatment of Hepatitis B and C and the Development of a Bioassay.
Project MD 990 The Development of Novel Pharmaceuticals for Specific Acute and Chronic Respiratory Conditions.
Project MD 2001 The Development of Novel Compounds as Non Antibiotic Feed Additives for the Poultry and Swine Industry.